EFG Asset Management North America Corp. Trims Position in IQVIA Holdings Inc. (NYSE:IQV)

EFG Asset Management North America Corp. decreased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 1.2% in the fourth quarter, HoldingsChannel.com reports. The fund owned 13,736 shares of the medical research company’s stock after selling 163 shares during the period. EFG Asset Management North America Corp.’s holdings in IQVIA were worth $2,701,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the stock. Prospera Financial Services Inc purchased a new position in shares of IQVIA during the third quarter valued at about $245,000. Avior Wealth Management LLC boosted its position in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 87 shares in the last quarter. Advisors Asset Management Inc. grew its holdings in shares of IQVIA by 74.3% during the 3rd quarter. Advisors Asset Management Inc. now owns 2,845 shares of the medical research company’s stock worth $674,000 after acquiring an additional 1,213 shares during the period. Intech Investment Management LLC bought a new position in shares of IQVIA in the 3rd quarter worth approximately $223,000. Finally, Eagle Asset Management Inc. lifted its stake in shares of IQVIA by 38.7% in the 3rd quarter. Eagle Asset Management Inc. now owns 12,733 shares of the medical research company’s stock valued at $2,791,000 after purchasing an additional 3,553 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 2.7 %

Shares of IQVIA stock opened at $181.07 on Wednesday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a twelve month low of $179.28 and a twelve month high of $253.84. The company has a market cap of $31.93 billion, a price-to-earnings ratio of 24.14, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The company’s 50 day moving average is $194.24 and its 200 day moving average is $207.29.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of research reports. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. JPMorgan Chase & Co. decreased their price target on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research note on Tuesday, February 18th. Truist Financial reissued a “buy” rating and set a $263.00 price objective (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Stifel Nicolaus decreased their target price on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. Five analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.